TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21414035
Drug: 3% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months
Study: 21414035
Drug: 3% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac in 2.5% hyaluronic acid gel for 6 months
Study: 21414035
Drug: 3% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months and 6 months
Study: 15105027
Drug: High-protein liquid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein liquid nutritional supplement (Boost HP)
Study: 15105027
Drug: Standard liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard liquid nutritional supplement (Ensure)
Study: 9589230
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g daily for 2 months)
Study: 9589230
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (6 g daily for 2 months)
Study: 2660451
Drug: UDCG 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCG 115 BS (5 mg)
Study: 2660451
Drug: UDCG 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCG 115 BS (10 mg)
Study: 2660451
Drug: UDCG 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCG 115 BS (chronic treatment: 2 x 5 or 2 x 10 mg/d)
Study: 30329038
Drug: Maribavir 800
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 800 mg twice daily
Study: 30329038
Drug: Maribavir 1200
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 1200 mg twice daily
Study: 30329038
Drug: Maribavir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (all doses combined)
Study: 28474460
Drug: OXN PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN PR (oxycodone-naloxone prolonged-release) at a mean daily dose of 130.7 mg (range 120-180 mg)
Study: 28474460
Drug: OXN PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN PR (oxycodone-naloxone prolonged-release)
Study: 21231888
Drug: Amitriptyline buccoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline buccoadhesive tablets
Study: 21231888
Drug: Amitriptyline buccoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline buccoadhesive tablets with high-viscosity hydroxypropylmethyl cellulose (HPMC-K4M)
Study: 21231888
Drug: Amitriptyline buccoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline buccoadhesive tablets with sodium carboxymethyl cellulose (NaCMC) and HPMC-E5LV
Study: 21231888
Drug: Amitriptyline buccoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline buccoadhesive tablets with HPMC-E5LV
Study: 19728577
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment (fixed appliance treatment)
Study: 10933062
Drug: Tirapazamine (TPZ)
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirapazamine (TPZ) administration
Study: 8569225
Drug: Ketanserin between
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin between 8 and 12 weeks of rHuEpo therapy
Study: 8569225
Drug: Ketanserin administration
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin administration
Study: 2037667
Drug: Intranasal bivalent
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal bivalent live attenuated influenza vaccine
Study: 2037667
Drug: Parenteral trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral trivalent inactivated subvirion vaccine
Study: 6909025
Drug: Timolol 5
Normalized name: timolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 5 mg/day + 1% adrenaline eye drops
Study: 6909025
Drug: Timolol 20
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 20 mg/day + 1% adrenaline eye drops
Study: 6909025
Drug: Timolol 5
Normalized name: timolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 5 mg/day + placebo eye drops
Study: 6909025
Drug: Timolol 20
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 20 mg/day + placebo eye drops
Study: 29463288
Drug: Dihydroartemisinin-piperaquine treatment
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine treatment administered through the local health system.
Study: 18083404
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with fluorouracil and folinic acid (n=1622)
Study: 16139122
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose before PCI and 75 mg daily for one year afterward
Study: 10456461
Drug: PAP levels
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP levels in patients receiving warfarin
Study: 21757914
Drug: Rebamipide 300
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 300 mg daily for 7 weeks
Study: 21757914
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 7 weeks
Study: 15139576
Drug: Adjustable dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Study: 15139576
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Study: 10796741
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate, bolus 30mg/kg over 15 minutes with a maintenance infusion of 5.4 mg/kg per hour for 23 hours.
Study: 10796741
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate, extended maintenance dose from 24 to 48 hours.
Study: 10796741
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate, therapy for whiplash injuries.
Study: 1751444
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (20 mmol sodium daily)
Study: 8312208
Drug: Azithromycin (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1g single dose)
Study: 30545921
Drug: Cyclophosphamide (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (440 mg/m2 days 1-5) / Etoposide (100 mg/m2 days 1-5) during part 2 of consolidation and delayed intensification
Study: 26218256
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control (target blood glucose, 4-7 mmol/L) with insulin titration based on blood glucose values and rate of change.
Study: 18469350
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (5.2 g daily for 12 weeks)
Study: 16517955
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 800 IU vitamin E and 500 mg vitamin C (n = 24)
Study: 16517955
Drug: B-group vitamins
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-group vitamins (5 mg folic acid, 5 mg vitamin B(2), 50 mg vitamin B(6), and 0.4 mg of vitamin B(12); n = 24)
Study: 10921768
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg once daily) with salmeterol placebo
Study: 10921768
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (100 microg daily) with montelukast placebo
Study: 8725733
Drug: Aspirin (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (330 mg/day)
Study: 8725733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiplatelet medication)
Study: 1533312
Drug: Pulsed intra-nasal
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed intra-nasal mupirocin ointment
Study: 3890132
Drug: L-carnitine, 2
Normalized name: L-Carnitine, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine, 2 g i.v. three times per week
Study: 29328027
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy (recombinant growth hormone injection once weekly for 12 months)
Study: 23207959
Drug: Imidafenacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin (0.1 mg twice daily)
Study: 30637134
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin therapy
Study: 22041946
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (aspirin alone)
Study: 17625501
Drug: Dapoxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 30 mg orally twice daily
Study: 17135729
Drug: Intravenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GLP-1 (0.9 pmol/kg/min)
Study: 17135729
Drug: Intravenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GLP-1 (0.9 pmol/kg/min) with a protein preload (400 ml protein shake)
Study: 17135729
Drug: Preload of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload of 400 ml water or 400 ml protein shake
Study: 11152378
Drug: Guanabenz (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (oral administration for 2 weeks)
Study: 9461727
Drug: Allergovit immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergovit immunotherapy
Study: 7530963
Drug: Tricyclic drugs
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic drugs
Study: 20696154
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg GMZ2 vaccine
Study: 18240099
Drug: Echinaforce tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinaforce tablets
Study: 18240099
Drug: Echinaforce Junior
Normalized name: Disprol Junior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinaforce Junior tablets
Study: 18240099
Drug: Echinacea sore
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea sore throat spray
Study: 16548353
Drug: Raw rhubarb
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw rhubarb (RR) 9 g/d
Study: 12834313
Drug: Immunoglobulin at
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin at doses of 50 mg/kg, 250 mg/kg, or 500 mg/kg weekly from day ‐7 to day 100 after transplantation
Study: 11728260
Drug: Lisinopril with
Normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril with ASA
Study: 11728260
Drug: Lisinopril without
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril without ASA
Study: 11728260
Drug: ASA and
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA and Lisinopril
Study: 1531677
Drug: Albuterol and
Normalized name: Albuterol and cromolyn only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol and ipratropium bromide
Study: 6374684
Drug: Proxyphylline (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxyphylline (2400 mg/day)
Study: 6374684
Drug: Theophylline (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (800 mg/day)
Study: 31278225
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of IV ondansetron at a dose of 0.2 mg/kg
Study: 27291501
Drug: Testosterone solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone solution 2% (TS)
Study: 20522464
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg for 5-12 years, 10 mg for >12 years)
Study: 18525261
Drug: 6-week antiretroviral
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week antiretroviral therapy interruption
Study: 18525261
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy interruption extended to viral set point
Study: 18525261
Drug: Resumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resumption of antiretroviral therapy
Study: 15996071
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg IL-1Ra
Study: 9569804
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy with local metronidazole administration
Study: 9569804
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy without local metronidazole administration
Study: 29196963
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene (TOR) 40 mg/day
Study: 29196963
Drug: Letrozole (LET)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (LET) 2.5 mg/day
Study: 26948184
Drug: 200-mg mifepristone
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg mifepristone followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Study: 26948184
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Study: 21749167
Drug: Experimental Treatment
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Treatment Group (ETG): plaque control and root planing plus amoxicillin and metronidazole
Study: 21749167
Drug: Control Treatment
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control Treatment Group (CTG): plaque control instructions, supragingival scaling, and two placebos
Study: 21749167
Drug: Experimental Treatment
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Treatment Group (ETG)
Study: 20729710
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream applied three times a week for 4 months
Study: 20729710
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied three times a week for 4 months
Study: 20729710
Drug: Open-label imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label imiquimod treatment for a further 4 months after initial treatment
Study: 20729710
Drug: Overall follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall follow-up after treatment
Study: 9814491
Drug: Isoproterenol (10(-6)
Normalized name: isoproterenol sulfate 0.6 MG/ML
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol (10(-6) mol/L)
Study: 8123955
Drug: Telephone contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone contact intervention (weekly calls from a healthcare professional during the first month of drug therapy)
Study: 2510286
Drug: Rioprostil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil + Aspirin
Study: 2510286
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Placebo
Study: 19004198
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Jiaji L4‐S1, Waiqiu (GB 36), Weizhong (BL 40), Xiaxi (GB 43) plus intervention injection of Gegensu Zhusheye (Puerarin Injectio)
Study: 19004198
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture combined with injection of Gegensu Zhusheye (Puerarin Injectio) into Ashi points
Study: 16600840
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention and referral to a nutritionist (from the beginning of olanzapine treatment in 9 patients)
Study: 16600840
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention and referral to a nutritionist (from the 9th week of therapy in 8 patients)
Study: 8970048
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg betamethasone + 4 cm3 of 1% lidocaine
Study: 8970048
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg betamethasone + 4 cm3 of 1% lidocaine
Study: 8970048
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg betamethasone + 4 cm3 of 1% lidocaine
Study: 1420996
Drug: IL-1ra (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra (1 mg/kg)
Study: 1420996
Drug: IL-1ra (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra (10 mg/kg)
Study: 1420996
Drug: IL-1ra (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra (1 mg/kg and 10 mg/kg)
Study: 22403770
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention
Study: 27785375
Drug: Bepotastine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine 10 mg tablets
Study: 22691101
Drug: Agrippal® (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agrippal® (trivalent vaccine)
Study: 22691101
Drug: Fluvirin® (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvirin® (control trivalent vaccine)
Study: 20130863
Drug: Prophylactic levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day)
Study: 20130863
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative LT4 treatment
Study: 20130863
Drug: Prophylactic levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-deficient patients
Study: 20130863
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative LT4 treatment among iodine-deficient patients
Study: 20130863
Drug: Prophylactic levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic levothyroxine (LT4) treatment (75‐125 microg/day) among iodine-sufficient patients
Study: 20130863
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative LT4 treatment among iodine-sufficient patients
Study: 18397716
Drug: Oral mizoribine
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mizoribine (MZB) pulse therapy, 10.0-19.7 mg/kg/d, maximum total dose 750 mg, given twice a week before a meal
Study: 18397716
Drug: Oral mizoribine
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mizoribine (MZB) pulse therapy
Study: 15850469
Drug: peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha-2b 1.5 mcg/kg plus oral ribavirin (1000 or 1200 mg/day)
Study: 7598771
Drug: rgp160 booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 booster injections
Study: 2164070
Drug: 2% lonapalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lonapalene ointment
Study: 30888959
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy for 23 months following one-month dual antiplatelet therapy (DAPT)
Study: 26089029
Drug: Cinacalcet (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (60 mg)
Study: 26089029
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg)
Study: 16839698
Drug: Enhanced Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Therapy group (n=27) with MEMS feedback and compliance enhancement counseling using CBT techniques
Study: 16839698
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care group (n=28) receiving weekly individual smoking cessation sessions only
Study: 15611571
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (testosterone enanthate, 600 mg/wk intramuscularly)
Study: 15611571
Drug: Acyline (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline (GnRH antagonist)
Study: 9003858
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (50 mg/day)
Study: 30036166
Drug: Home Telemonitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Telemonitoring (HTM) with weekly video televisits and daily vital sign monitoring
Study: 30036166
Drug: Comprehensive Outpatient
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Outpatient Management (COM) with weekly telephone contact
Study: 29374412
Drug: Positive FIT
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive FIT results (cut-off 100 ng/mL)